GLOBE Score and UK ‐ PBC Risk Score Predict Long‐Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate
Journal of Digestive Diseases · 2025
DOI: 10.1111/1751-2980.13359 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Digestive Diseases, 2025. Verfasst von Shu Xiang Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Fenofibrate, Ursodeoxycholic Acid, Liver Cirrhosis, Biliary, Cholagogues and Choleretics. Die Arbeit nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
Fenofibrate is widely used as add‐on therapy for patients with primary biliary cholangitis (PBC) who have a suboptimal response to ursodeoxycholic acid (UDCA). We aimed to evaluate whether the UDCA biochemical response criteria, especially the GLOBE and UK‐PBC risk scoring systems, could predict the long‐term prognosis of PBC patients who received fenofibrate add‐on therapy.
Methods
PBC patients receiving fenofibrate add‐on therapy were included in this retrospective–prospective study. We compared the utility of nine biochemical response criteria and two scoring systems to predict clinical outcomes by Kaplan–Meier plots and the receiver operating characteristic (ROC) curve analysis.
Results
Sixty‐three patients were included in this study, of whom 11 had a poor outcome (hepatic decompensation, liver‐related death, or liver transplantation) and 52 had a good outcome. After a median follow‐up of 45 months, fenofibrate add‐on therapy steadily decreased the serum levels of alkaline phosphatase, γ‐glutamyl transferase, and alanine aminotransferase in both groups. The patients with poor outcomes had a higher GLOBE score and UK‐PBC risk score than those with good outcomes after 12 months of treatment. More importantly, both scores had better predictive performance for hepatic decompensation‐ and transplant‐free survival than the other criteria. The areas under the ROC curve of the GLOBE and UK‐PBC risk scores at 12 months were 0.878 (95% confidence interval [CI] 0.751–0.955) and 0.919 (95% CI 0.803–0.978), respectively.
Conclusion
The GLOBE and UK‐PBC risk scores outperformed the other biochemical response criteria in predicting the clinical outcomes of PBC patients with suboptimal response to UDCA and receiving fenofibrate add‐on therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- State Key Laboratory of Digestive Health, Beijing, China.
- National Clinical Research Center for Digestive Diseases, Beijing, China.
- Center for Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Yuan Yuan Kong, Xin Yan Zhao, Hong You, Ji Dong Jia
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, S. X., Li, B. E., Li, M., Chen, S., Lyu, T. T., Wang, Q. Y., Wang, X. M., Wang, Y., Ma, H., Ou, X. J., Kong, Y. Y., Zhao, X. Y., You, H., Duan, W. J., & Jia, J. D. (2025). GLOBE Score and UK ‐ PBC Risk Score Predict Long‐Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13359
Vancouver
Li SX, Li BE, Li M, Chen S, Lyu TT, Wang QY, et al. GLOBE Score and UK ‐ PBC Risk Score Predict Long‐Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate. Journal of Digestive Diseases. 2025. doi:10.1111/1751-2980.13359
BibTeX
@article{Li2025,
author = {Li, Shu Xiang and Li, Bu Er and Li, Min and Chen, Sha and Lyu, Ting Ting and Wang, Qian Yi and Wang, Xiao Ming and Wang, Yu and Ma, Hong and Ou, Xiao Juan and Kong, Yuan Yuan and Zhao, Xin Yan and You, Hong and Duan, Wei Jia and Jia, Ji Dong},
title = {GLOBE Score and UK ‐ PBC Risk Score Predict Long‐Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate},
journal = {Journal of Digestive Diseases},
year = {2025},
doi = {10.1111/1751-2980.13359}
}
EUVIMED